RU2019121646A - Способы и композиции для лечения легочной гипертензии и других заболеваний легких - Google Patents
Способы и композиции для лечения легочной гипертензии и других заболеваний легких Download PDFInfo
- Publication number
- RU2019121646A RU2019121646A RU2019121646A RU2019121646A RU2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A RU 2019121646 A RU2019121646 A RU 2019121646A
- Authority
- RU
- Russia
- Prior art keywords
- vasodilator
- carrier
- subject
- pharmaceutical composition
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434185P | 2016-12-14 | 2016-12-14 | |
| US62/434,185 | 2016-12-14 | ||
| PCT/US2017/066519 WO2018112258A1 (en) | 2016-12-14 | 2017-12-14 | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019121646A true RU2019121646A (ru) | 2021-01-15 |
| RU2019121646A3 RU2019121646A3 (https=) | 2021-03-17 |
Family
ID=60888760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121646A RU2019121646A (ru) | 2016-12-14 | 2017-12-14 | Способы и композиции для лечения легочной гипертензии и других заболеваний легких |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10912778B2 (https=) |
| EP (2) | EP4620525A3 (https=) |
| JP (3) | JP2020502121A (https=) |
| CN (1) | CN110381951A (https=) |
| AU (3) | AU2017378409A1 (https=) |
| BR (1) | BR112019012251A2 (https=) |
| CA (1) | CA3046025A1 (https=) |
| MX (1) | MX2019006938A (https=) |
| RU (1) | RU2019121646A (https=) |
| WO (1) | WO2018112258A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2938343B1 (en) | 2012-12-21 | 2018-09-12 | Mayo Foundation For Medical Education And Research | Methods and materials for treating calcific aortic valve stenosis |
| US10898494B2 (en) | 2016-05-05 | 2021-01-26 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| EP4620525A3 (en) | 2016-12-14 | 2025-12-03 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| WO2018132371A2 (en) * | 2017-01-10 | 2018-07-19 | United Therapeutics Corporation | Methods and compositions for treating pulmonary hypertension |
| WO2020210707A1 (en) * | 2019-04-10 | 2020-10-15 | Mayo Foundation For Medical Education And Research | Methods and materials for gender-dependent treatment of cardiovascular dysfunction |
| KR20220019027A (ko) * | 2019-06-10 | 2022-02-15 | 레스피라 테라퓨틱스 인크. | 담체-기반 제제 및 관련 방법 |
| CN112569210B (zh) * | 2019-09-27 | 2023-09-15 | 盈科瑞（天津）创新医药研究有限公司 | 一种吸入用马昔腾坦溶液及其制备方法 |
| CN112773898A (zh) * | 2019-11-11 | 2021-05-11 | 广州华真医药科技有限公司 | 磷酸二酯酶5抑制剂在制备抗纤维化疾病药物中的应用 |
| CN110946826B (zh) * | 2019-12-12 | 2022-02-22 | 烟台大学 | 一种利奥西呱口服制剂及其制备方法 |
| JP7727652B2 (ja) | 2020-03-31 | 2025-08-21 | インヴォックス ベルジアム エヌヴイ | 少なくとも２つの液体組成物のエアロゾル送達 |
| US11013688B1 (en) * | 2020-05-28 | 2021-05-25 | Softhale Nv | Methods of treatment of viral diseases |
| KR20230096998A (ko) * | 2020-10-28 | 2023-06-30 | 인스메드 인코포레이티드 | 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법 |
| US20250000873A1 (en) | 2021-09-10 | 2025-01-02 | Justus-Liebig-Universitaet Giessen | Inhaled iloprost for rescue treatment and treatment as needed in pulmonary hypertension |
| CN121843699A (zh) * | 2023-05-31 | 2026-04-10 | 瑞必治公司 | 肺动脉高压治疗方法 |
| CN116687888A (zh) * | 2023-06-02 | 2023-09-05 | 苏州易合医药有限公司 | 伐地那非和达泊西汀复方干粉吸入制剂及其制备方法 |
| CN121714543A (zh) * | 2024-09-23 | 2026-03-24 | 上海欣药智能科技有限公司 | 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1338235A (en) | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
| GB1493685A (en) | 1970-12-15 | 1977-11-30 | May & Baker Ltd | 8-azapurinones |
| US4883810A (en) | 1976-08-17 | 1989-11-28 | Burroughs Wellcome Co. | Ethers |
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| DE3417638A1 (de) | 1984-05-10 | 1985-11-14 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur bestimmung geringer stoffmengen von arzneimitteln, von koerpereigenen oder anderen chemischen substanzen in biologischem material |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6441245B1 (en) | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| US6362178B1 (en) | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| EA004872B1 (ru) | 1999-08-03 | 2004-08-26 | ЛИЛЛИ АЙКОС эЛ-эЛ-Си | β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| EP1219609B1 (en) | 1999-09-16 | 2007-04-04 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogenous six-membered ring compounds |
| NZ524572A (en) | 2000-09-06 | 2004-08-27 | Tanabe Seiyaku Co | Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions |
| WO2002079143A1 (en) | 2001-03-28 | 2002-10-10 | Pfizer Limited | N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad |
| TWI316055B (https=) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US20040077624A1 (en) | 2002-05-23 | 2004-04-22 | Pfizer Inc. | Novel combination |
| CA2536293A1 (en) * | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating copd and pulmonary hypertension |
| JP2008546786A (ja) | 2005-06-23 | 2008-12-25 | シェーリング コーポレイション | Ｐｄｅ５インヒビターの迅速吸収性経口処方物 |
| CA2641393C (en) | 2006-02-03 | 2014-12-16 | Scidose Llc | Novel epoprostenol formulation and method of making thereof |
| CN101495122B (zh) | 2006-05-15 | 2011-10-05 | 联合治疗公司 | 使用定量吸入器给予曲前列尼 |
| KR20160048222A (ko) | 2007-12-17 | 2016-05-03 | 유나이티드 세러퓨틱스 코오포레이션 | 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법 |
| WO2009086470A2 (en) | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
| KR20230085944A (ko) | 2008-03-18 | 2023-06-14 | 아레나 파마슈티칼스, 인크. | 프로스타시클린 （ｐｇｉ２） 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제 |
| WO2009115235A1 (en) | 2008-03-20 | 2009-09-24 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of pulmonary hypertension |
| LT2315587T (lt) | 2008-08-13 | 2018-01-10 | Actelion Pharmaceuticals Ltd. | Terapinės kompozicijos, turinčios macitentano |
| KR20170024165A (ko) | 2009-06-26 | 2017-03-06 | 니뽄 신야쿠 가부시키가이샤 | 결정 |
| WO2011030351A2 (en) | 2009-09-03 | 2011-03-17 | Rubicon Research Private Limited | Taste - masked pharmaceutical compositions |
| EP2480526A1 (en) | 2009-09-23 | 2012-08-01 | Arena Pharmaceuticals, Inc. | Crystalline forms and processes for the preparation of pgi2 receptor agonists |
| EP3108888B1 (en) * | 2010-03-15 | 2020-02-12 | United Therapeutics Corporation | Treatment for pulmonary hypertension |
| WO2011137734A1 (en) | 2010-05-03 | 2011-11-10 | Tsh Biopharm Company, Limited | Pharmaceutical composition and method for treating hypertension |
| EP2593452B1 (en) | 2010-07-14 | 2017-01-18 | Novartis AG | Ip receptor agonist heterocyclic compounds |
| EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| US8561609B2 (en) | 2010-12-07 | 2013-10-22 | Respira Therapeutics, Inc. | Dry powder inhaler |
| US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
| CN104853744B (zh) | 2012-10-31 | 2018-01-19 | 维克多瑞有限责任公司 | 气溶胶化伊洛前列素的给药 |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| EP3110484A4 (en) | 2014-02-21 | 2018-02-14 | Respira Therapeutics, Inc. | Powder inhaler, system and methods |
| EP3244968B1 (en) * | 2015-01-13 | 2023-08-30 | Vivus LLC | Combination therapy for pulmonary hypertension |
| EP4620525A3 (en) | 2016-12-14 | 2025-12-03 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
-
2017
- 2017-12-14 EP EP25178206.6A patent/EP4620525A3/en active Pending
- 2017-12-14 WO PCT/US2017/066519 patent/WO2018112258A1/en not_active Ceased
- 2017-12-14 MX MX2019006938A patent/MX2019006938A/es unknown
- 2017-12-14 US US16/469,524 patent/US10912778B2/en active Active
- 2017-12-14 BR BR112019012251-6A patent/BR112019012251A2/pt unknown
- 2017-12-14 EP EP17823002.5A patent/EP3554507A1/en not_active Ceased
- 2017-12-14 CN CN201780086527.2A patent/CN110381951A/zh active Pending
- 2017-12-14 JP JP2019531750A patent/JP2020502121A/ja active Pending
- 2017-12-14 AU AU2017378409A patent/AU2017378409A1/en not_active Abandoned
- 2017-12-14 CA CA3046025A patent/CA3046025A1/en active Pending
- 2017-12-14 RU RU2019121646A patent/RU2019121646A/ru unknown
-
2021
- 2021-01-11 US US17/146,173 patent/US11491160B2/en active Active
- 2021-11-23 US US17/534,282 patent/US11491161B2/en active Active
-
2022
- 2022-06-29 US US17/853,005 patent/US12263174B2/en active Active
- 2022-10-17 AU AU2022256085A patent/AU2022256085A1/en not_active Abandoned
- 2022-12-09 JP JP2022197348A patent/JP2023036678A/ja active Pending
-
2025
- 2025-02-10 JP JP2025019782A patent/JP2025065408A/ja active Pending
- 2025-02-26 US US19/064,180 patent/US20250195531A1/en active Pending
- 2025-11-03 AU AU2025260006A patent/AU2025260006A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11491160B2 (en) | 2022-11-08 |
| JP2025065408A (ja) | 2025-04-17 |
| US20220347183A1 (en) | 2022-11-03 |
| US20210205318A1 (en) | 2021-07-08 |
| JP2023036678A (ja) | 2023-03-14 |
| US11491161B2 (en) | 2022-11-08 |
| BR112019012251A2 (pt) | 2019-11-05 |
| AU2022256085A1 (en) | 2022-11-17 |
| US20200093830A1 (en) | 2020-03-26 |
| JP2020502121A (ja) | 2020-01-23 |
| AU2025260006A1 (en) | 2025-11-20 |
| US20220079949A1 (en) | 2022-03-17 |
| CA3046025A1 (en) | 2018-06-21 |
| EP3554507A1 (en) | 2019-10-23 |
| CN110381951A (zh) | 2019-10-25 |
| US12263174B2 (en) | 2025-04-01 |
| US10912778B2 (en) | 2021-02-09 |
| US20250195531A1 (en) | 2025-06-19 |
| RU2019121646A3 (https=) | 2021-03-17 |
| WO2018112258A1 (en) | 2018-06-21 |
| EP4620525A3 (en) | 2025-12-03 |
| MX2019006938A (es) | 2019-09-06 |
| AU2017378409A1 (en) | 2019-07-04 |
| EP4620525A2 (en) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019121646A (ru) | Способы и композиции для лечения легочной гипертензии и других заболеваний легких | |
| JP2020502121A5 (https=) | ||
| JP6669808B2 (ja) | 超低密度肺粉剤 | |
| JP2023036678A5 (https=) | ||
| CN1972730A (zh) | 格隆溴铵用于治疗儿童哮喘 | |
| JP2025122121A (ja) | 肺線維症を処置するための方法及び組成物 | |
| CA2888994C (en) | Levodopa formulations for rapid relief of parkinson's disease | |
| EP2957552B1 (en) | Vilanterol formulations | |
| EP2957551B1 (en) | Dry powder formulations comprising vilanterol | |
| KR20250002714A (ko) | 폐 질환을 치료하기 위한 방법 및 조성물 | |
| WO2023154705A1 (en) | Treprostinil iloprost combination therapy | |
| JP2026509493A (ja) | 噴霧乾燥トレプロスチニル製剤 | |
| HK40096956A (zh) | 治疗肺纤维化的方法和组合物 | |
| CA2888979C (en) | Reducing inter-patient variability of levodopa plasma concentrations | |
| EP2957550A1 (en) | Pharmaceutical formulations comprising vilanterol |